BACKGROUND: Significant improvements in the survival of women with breast cancer have been observed and are attributed to a multidisciplinary approach and the introduction of polychemotherapy and endocrine regimens. The objective of this population-based study was to determine whether women with inflammatory breast cancer (IBC) who received treatment in a modern era had a poorer survival compared those with non-IBC locally advanced breast cancer (LABC). METHODS: The Surveillance, Epidemiology, and End Results program registry was searched to identify women with stage IIIB/C breast cancer diagnosed between 2004 and 2007 who had undergone surgery and radiotherapy. Patients were categorized as either having IBC or non-IBC LABC according the sixth edition of the American Joint Committee on Cancer (AJCC) criteria. Breast cancer-specific survival (BCS) was estimated using the Kaplan-Meier product limit method and compared across groups using the log-rank statistic. Cox models were then fitted to compare the association between breast cancer type and BCS after adjusting for patient and tumor characteristics. RESULTS: A total of 828 (19.2%) women and 3476 (80.8%) women had stage IIIB/C IBC and non-IBC LABC, respectively. The median follow-up was 19 months. The 2-year BCS rate was 90% (95% confidence interval [95% CI], 88%-91%) for the entire cohort and 84% (95%CI, 80%-87%) and 91% (95%CI, 90%-91%) among women with IBC and non-IBC LABC, respectively. In the multivariable model, patients with IBC were found to have a 43% increased risk of death from breast cancer compared with patients with non-IBC LABC (hazard ratio, 1.43; 95%CI, 1.10-1.86 [P = .008]). CONCLUSIONS: In the era of multidisciplinary management and anthracycline-based and taxane-based polychemotherapy regimens, women with IBC continue to have worse survival outcomes compared with those with non-IBC LABC.
BACKGROUND: Significant improvements in the survival of women with breast cancer have been observed and are attributed to a multidisciplinary approach and the introduction of polychemotherapy and endocrine regimens. The objective of this population-based study was to determine whether women with inflammatory breast cancer (IBC) who received treatment in a modern era had a poorer survival compared those with non-IBC locally advanced breast cancer (LABC). METHODS: The Surveillance, Epidemiology, and End Results program registry was searched to identify women with stage IIIB/C breast cancer diagnosed between 2004 and 2007 who had undergone surgery and radiotherapy. Patients were categorized as either having IBC or non-IBC LABC according the sixth edition of the American Joint Committee on Cancer (AJCC) criteria. Breast cancer-specific survival (BCS) was estimated using the Kaplan-Meier product limit method and compared across groups using the log-rank statistic. Cox models were then fitted to compare the association between breast cancer type and BCS after adjusting for patient and tumor characteristics. RESULTS: A total of 828 (19.2%) women and 3476 (80.8%) women had stage IIIB/C IBC and non-IBC LABC, respectively. The median follow-up was 19 months. The 2-year BCS rate was 90% (95% confidence interval [95% CI], 88%-91%) for the entire cohort and 84% (95%CI, 80%-87%) and 91% (95%CI, 90%-91%) among women with IBC and non-IBC LABC, respectively. In the multivariable model, patients with IBC were found to have a 43% increased risk of death from breast cancer compared with patients with non-IBC LABC (hazard ratio, 1.43; 95%CI, 1.10-1.86 [P = .008]). CONCLUSIONS: In the era of multidisciplinary management and anthracycline-based and taxane-based polychemotherapy regimens, women with IBC continue to have worse survival outcomes compared with those with non-IBC LABC.
Authors: H Arias-Pulido; A Cimino-Mathews; N Chaher; C Qualls; N Joste; C Colpaert; J D Marotti; M Foisey; E R Prossnitz; L A Emens; S Fiering Journal: Breast Cancer Res Treat Date: 2018-06-01 Impact factor: 4.872
Authors: Julie S Wecsler; Welela Tereffe; Rose C Pedersen; Michelle R Sieffert; Wendy J Mack; Haiyan Cui; Christy A Russell; Ryan R Woods; Rebecca K Viscusi; Stephen F Sener; Julie E Lang Journal: Breast Cancer Res Treat Date: 2015-04-07 Impact factor: 4.872
Authors: Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver Journal: Breast Cancer Res Treat Date: 2012-06-26 Impact factor: 4.872
Authors: H Masuda; T M Brewer; D D Liu; T Iwamoto; Y Shen; L Hsu; J S Willey; A M Gonzalez-Angulo; M Chavez-MacGregor; T M Fouad; W A Woodward; J M Reuben; V Valero; R H Alvarez; G N Hortobagyi; N T Ueno Journal: Ann Oncol Date: 2013-12-18 Impact factor: 32.976
Authors: Jieqiong Liu; Kai Chen; Wen Jiang; Kai Mao; Shunrong Li; Min Ji Kim; Qiang Liu; Lisa K Jacobs Journal: J Cancer Res Clin Oncol Date: 2016-10-04 Impact factor: 4.553
Authors: Tamer M Fouad; Angelica M Gutierrez Barrera; James M Reuben; Anthony Lucci; Wendy A Woodward; Michael C Stauder; Bora Lim; Sarah M DeSnyder; Banu Arun; Babiera Gildy; Vicente Valero; Gabriel N Hortobagyi; Naoto T Ueno Journal: Lancet Oncol Date: 2017-04 Impact factor: 41.316
Authors: Taiwo Adesoye; Oluwatowo Babayemi; Lauren M Postlewait; Sarah M DeSnyder; Susie X Sun; Wendy A Woodward; Naoto T Ueno; Kelly K Hunt; Anthony Lucci; Mediget Teshome Journal: Ann Surg Oncol Date: 2021-07-22 Impact factor: 5.344